<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial emergency management of severe COPD exacerbations: Rapid overview of emergency management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial emergency management of severe COPD exacerbations: Rapid overview of emergency management</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial emergency management of severe COPD exacerbations: Rapid overview of emergency management</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="highlight_gray_text"><strong class="heading">Clinical features</strong></td> </tr> <tr> <td class="indent1">Features of COPD exacerbation: Diffuse wheezing, distant breath sounds, barrel-shaped chest, tachypnea, tachycardia, smoking &gt;20 pack years.</td> </tr> <tr> <td class="indent1">Features of severe respiratory insufficiency: Use of accessory muscles; brief, fragmented speech; inability to lie supine; profound diaphoresis; agitation; asynchrony between chest and abdominal motion with respiration; failure to improve with initial emergency treatment.</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Features of impending respiratory arrest:</strong> Inability to maintain respiratory effort, cyanosis, hemodynamic instability, and depressed mental status</td> </tr> <tr> <td class="indent1">Features of cor pulmonale: Jugular venous distension, prominent left parasternal heave, peripheral edema.</td> </tr> <tr> <td class="indent1">COPD exacerbations are most often precipitated by infection (viral or bacterial).</td> </tr> <tr> <td class="indent1">Severe respiratory distress in a patient with known or presumed COPD can be due to an exacerbation of COPD or a comorbid process, such as acute coronary syndrome, decompensated heart failure, pulmonary embolism, pneumonia, pneumothorax, sepsis.</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Management</strong></td> </tr> <tr> <td class="indent1">Assess patient's airway, breathing, and circulation; secure as necessary.</td> </tr> <tr> <td class="indent1">Provide supplemental oxygen to target a pulse oxygen saturation of 88 to 92% or <span class="nowrap_whitespace">PaO<sub>2</sub></span> of 60 to 70 mmHg (7.98 to 9.31 kPa); Venturi mask can be useful for titrating <span class="nowrap_whitespace">FiO<sub>2</sub>;</span> <span class="nowrap_whitespace">high FiO<sub>2</sub></span> usually not needed and can contribute to hypercapnia (high <span class="nowrap_whitespace">FiO<sub>2</sub></span> requirement should prompt consideration of alternative diagnosis [eg, PE]).</td> </tr> <tr> <td class="indent1">Determine patient preferences regarding intubation based on direct questioning or advance directive whenever possible.</td> </tr> <tr> <td class="indent1">Provide combination of aggressive bronchodilator therapy and ventilatory support (NIV or invasive ventilation).</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Noninvasive ventilation (NIV):</strong> Appropriate for the majority of patients with severe exacerbations of COPD unless immediate intubation is needed or NIV is otherwise contraindicated</td> </tr> <tr> <td class="indent1">Contraindications to NIV include: Severely impaired consciousness, inability to clear secretions or protect airway, high aspiration risk.</td> </tr> <tr> <td class="indent1">Initial settings for bilevel NIV: 8 cm <span class="nowrap_whitespace">H<sub>2</sub>O</span> inspiratory pressure (may increase up to 15 cm <span class="nowrap_whitespace">H<sub>2</sub>O</span> if needed to aid ventilation); 3 cm <span class="nowrap_whitespace">H<sub>2</sub>O</span> expiratory pressure.</td> </tr> <tr> <td class="indent1">Administer bronchodilators via nebulizer or MDI: Nebulizer usually requires interruption of NIV; MDIs can be delivered in line using adaptor (refer to dosing below).</td> </tr> <tr> <td class="indent1">Obtain ABG after two hours of NIV and compare with baseline: Worsening or unimproved gas exchange and pH &lt;7.25 are indications for invasive ventilation.</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Tracheal intubation and mechanical ventilation:</strong> Indicated for patients with acute respiratory failure, hemodynamic instability (eg, heart rate &lt;50/minute, uncontrolled arrhythmia) and those in whom NIV is contraindicated or who fail to improve with NIV and aggressive pharmacotherapy</td> </tr> <tr> <td class="indent1">Rapid sequence induction (eg, etomidate, ketamine, or propofol).</td> </tr> <tr> <td class="indent1">Intubate with #8 endotracheal tube (8 mm internal diameter) or larger, if possible.</td> </tr> <tr> <td class="indent1">Initial ventilator settings aim to maintain adequate oxygenation and ventilation while minimizing elevated airway pressures: SIMV, tidal volume 6 to 8 mL/kg, respiratory rate 10 to 12/minute, inspiratory flow rate 60 to 80 L/min (increase if needed to enable longer expiratory phase), PEEP 5 cm <span class="nowrap_whitespace">H<sub>2</sub>O.</span> May need to tolerate elevated <span class="nowrap_whitespace">PaCO<sub>2</sub></span> to avoid barotrauma (ie, permissive hypercapnia). In patients with chronic hypercapnia, aim for <span class="nowrap_whitespace">PaCO<sub>2</sub></span> close to baseline.</td> </tr> <tr> <td class="indent1">Administer inhaled bronchodilator therapy: Usually via MDI with in-line adaptor (refer to dosing below).</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Diagnostic testing</strong></td> </tr> <tr> <td class="indent1">Assess oxygen saturation with continuous pulse oximetry.</td> </tr> <tr> <td class="indent1">Obtain ABG in all patients with severe COPD exacerbation.</td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">ETCO<sub>2</sub></span> monitoring (capnography) has only moderate correlation with arterial <span class="nowrap_whitespace">PaCO<sub>2</sub></span> in COPD exacerbations.</td> </tr> <tr> <td class="indent1">Do not assess peak expiratory flow or spirometry in acute severe COPD exacerbations as results are not accurate.</td> </tr> <tr> <td class="indent1">Obtain portable chest radiograph: Look for signs of pneumonia, acute heart failure, pneumothorax.</td> </tr> <tr> <td class="indent1">When evidence of acute infection (eg, purulent phlegm, pneumonia) is absent and chest radiograph is unrevealing, obtain CT pulmonary angiogram for possible pulmonary embolism.</td> </tr> <tr> <td class="indent1">Obtain complete blood count, electrolytes (Na+, K+, <span class="nowrap_whitespace">Cl–,</span> <span class="nowrap_whitespace">HCO3–),</span> BUN, and creatinine; also obtain cardiac troponin, BNP, or NT-proBNP, if diagnosis is uncertain.</td> </tr> <tr> <td class="indent1">Test for influenza infection during influenza season.*</td> </tr> <tr> <td class="indent1">Obtain ECG: Look for arrhythmia, ischemia, cor pulmonale.</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Pharmacotherapy</strong></td> </tr> <tr> <td class="indent1">Inhaled beta agonist: Albuterol 2.5 mg diluted to 3 mL via nebulizer or 2 to 4 inhalations from MDI every hour for 2 or 3 doses; up to 8 inhalations may be used for intubated patients, if needed.</td> </tr> <tr> <td class="indent1">Short-acting muscarinic antagonist (anticholinergic agent): Ipratropium 500 micrograms (can be combined with albuterol) in 3 mL via nebulizer or 2 to 4 inhalations from MDI every hour for 2 to 3 doses.</td> </tr> <tr> <td class="indent1">Intravenous glucocorticoid (eg, methylprednisolone 60 mg to 125 mg IV, repeat every 6 to 12 hours).</td> </tr> <tr> <td class="indent1">Antibiotic therapy*: Appropriate for majority of severe COPD exacerbations; select antibiotic based on likelihood of particular pathogens (eg, <em>Pseudomonas</em> risk factors<sup>¶</sup>, prior sputum cultures, local patterns of resistance).</td> </tr> <tr> <td class="indent2"> <ul> <li>No <em>Pseudomonas</em> risk factor(s)<sup>¶</sup>: Ceftriaxone 1 to 2 grams IV, <strong>or</strong> cefotaxime 1 to 2 grams IV, <strong>or</strong> levofloxacin 500 mg IV or orally, <strong>or</strong> moxifloxacin 400 mg IV or orally</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li><em>Pseudomonas</em> risk factor(s)<sup>¶</sup>: Piperacillin-tazobactam 4.5 grams IV, <strong>or</strong> cefepime 2 grams IV, <strong>or</strong> ceftazidime 2 grams IV</li> </ul> </td> </tr> <tr> <td class="indent1">Antiviral therapy (influenza suspected)*: Oseltamivir 75 mg orally every 12 hours <strong>or</strong> peramivir 600 mg IV once (for patients unable to take oral medication).</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Monitoring</strong></td> </tr> <tr> <td class="indent1">Perform continual monitoring of oxygen saturation, blood pressure, heart rate, respiratory rate.</td> </tr> <tr> <td class="indent1">Close monitoring of respiratory status.</td> </tr> <tr> <td class="indent1">Continuous ECG monitoring.</td> </tr> <tr> <td class="indent1">Monitor blood glucose.</td> </tr> <tr> <td class="highlight_gray_text"><strong class="heading">Disposition</strong></td> </tr> <tr> <td class="indent1">Criteria for ICU admission include:</td> </tr> <tr> <td class="indent2"> <ul> <li>Patients with high-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes mellitus, renal failure, liver failure)</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Continued need for NIV or invasive ventilation</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Hemodynamic instability</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Need for frequent nebulizer treatments or monitoring</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>COPD: chronic obstructive pulmonary disease; <span class="nowrap_whitespace">PaO<sub>2</sub>:</span> arterial tension of oxygen; <span class="nowrap_whitespace">FiO<sub>2</sub>:</span> fraction of inspired oxygen; PE: pulmonary embolism; NIV: noninvasive ventilation; MDI: metered dose inhaler; ABG: arterial blood gas; SIMV: synchronized intermittent mechanical ventilation; PEEP: positive end-expiratory pressure; <span class="nowrap_whitespace">PaCO<sub>2</sub>:</span> arterial tension of carbon dioxide; <span class="nowrap_whitespace">ETCO<sub>2</sub>:</span> end-tidal carbon dioxide; BUN: blood urea nitrogen; BNP: brain natriuretic peptide; NT-ProBNP: N-terminal pro-BNP; ECG: electrocardiogram; IV: intravenous; ICU: intensive care unit.</p>
<p>* When influenza is suspected, therapy should not be delayed while awaiting results of testing. Doses shown are for patients with normal renal function. Some agents require dose adjustment for renal impairment; refer to separate UpToDate algorithms of antibiotic treatment of exacerbations of COPD.</p>
¶ <em>Pseudomonas</em> infection risk factors: Broad spectrum antibiotic use in the past 3 months; chronic colonization or previous isolation of Pseudomonas aeruginosa from sputum (particularly in past 12 months); very severe underlying COPD <span class="nowrap_whitespace">(FE<sub>V</sub>1</span> &lt;30% predicted); chronic systemic glucocorticoid use.</div><div id="graphicVersion">Graphic 65420 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
